{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:59:26Z","timestamp":1792483166189,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.bone.2021.116298","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T18:50:28Z","timestamp":1639248628000},"page":"116298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery"],"prefix":"10.1016","volume":"155","author":[{"given":"Masafumi","family":"Kashii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kamatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayanori","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Kuriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2021.116298_bb0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-011-0060-1","article-title":"Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the international osteoporosis foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"6","author":"Str\u00f6m","year":"2011","journal-title":"Arch. Osteoporos."},{"issue":"Suppl 4","key":"10.1016\/j.bone.2021.116298_bb0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00198-010-1398-8","article-title":"Management of osteoporosis in patients hospitalized for hip fractures","volume":"21","author":"Ip","year":"2010","journal-title":"Osteoporos. Int."},{"issue":"10","key":"10.1016\/j.bone.2021.116298_bb0015","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/jbmr.1698","article-title":"ASBMR task force on secondary fracture prevention, making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention","volume":"27","author":"Eisman","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2021.116298_bb0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.3877","article-title":"Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition","volume":"35","author":"Conley","year":"2020","journal-title":"J. Bone Miner. Res."},{"issue":"23","key":"10.1016\/j.bone.2021.116298_bb0025","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1001\/jama.298.23.2761","article-title":"Long-term risk of incident vertebral fractures","volume":"298","author":"Cauley","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bone.2021.116298_bb0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/ard.2008.092775","article-title":"Clinical subsequent fractures cluster in time after first fractures","volume":"68","author":"van Geel","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bone.2021.116298_bb0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","article-title":"Risk of subsequent fracture after prior fracture among older women","volume":"30","author":"Balasubramanian","year":"2019","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bone.2021.116298_bb0040","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00198-011-1556-7","article-title":"Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly japanese women","volume":"23","author":"Osaki","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"18","key":"10.1016\/j.bone.2021.116298_bb0045","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2021.116298_bb0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00198-012-2024-8","article-title":"Analysis of the association between bisphosphonate treatment survival in danish hip fracture patients\u2014a nationwide register-based open cohort study","volume":"24","author":"Bondo","year":"2013","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2021.116298_bb0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00198-013-2420-8","article-title":"Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON recurrent fracture trial","volume":"25","author":"Prieto-Alhambra","year":"2014","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2021.116298_bb0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11657-017-0316-5","article-title":"Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States","volume":"12","author":"Durden","year":"2017","journal-title":"Arch. Osteoporos."},{"issue":"6","key":"10.1016\/j.bone.2021.116298_bb0065","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"issue":"9","key":"10.1016\/j.bone.2021.116298_bb0070","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid","volume":"95","author":"Reid","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2021.116298_bb0075","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00198-011-1563-8","article-title":"Treatment with acetaminophen\/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg","volume":"23","author":"Wark","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bone.2021.116298_bb0080","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00774-019-01050-8","article-title":"Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study","volume":"38","author":"Okimoto","year":"2020","journal-title":"J. Bone Miner. Metab."},{"issue":"18","key":"10.1016\/j.bone.2021.116298_bb0085","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2021.116298_bb0090","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/ki.2014.328","article-title":"The definition of acute kidney injury and its use in practice","volume":"87","author":"Thomas","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2021.116298_bb0095","doi-asserted-by":"crossref","DOI":"10.1007\/s00223-021-00884-7","article-title":"Acute phase reactions after intravenous infusion of zoledronic acid in japanese patients with osteoporosis: sub-analyses of the phase III ZONE study","author":"Shiraki","year":"2021","journal-title":"Calcif Tissue Int."},{"issue":"5","key":"10.1016\/j.bone.2021.116298_bb0100","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00774-021-01231-4","article-title":"Early adverse events after the first administration of zoledronic acid in Japanese patients with osteoporosis","volume":"39","author":"Takada","year":"2021","journal-title":"J. Bone Miner. Metab."},{"issue":"1","key":"10.1016\/j.bone.2021.116298_bb0105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00198-016-3736-y","article-title":"Efficacy and safety of once-yearly zoledronic acid in japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in efficacy to osteoporosis; ZONE study)","volume":"28","author":"Nakamura","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bone.2021.116298_bb0110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","article-title":"Peripheral blood monocytes are responsible for \u03b3\u03b4 T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP","volume":"144","author":"Roelofs","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bone.2021.116298_bb0115","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jbmr.521","article-title":"Circulating \u03b3\u03b4 T cells and the risk of acute-phase response after zoledronic acid administration","volume":"27","author":"Rossini","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2021.116298_bb0120","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/jbmr.1797","article-title":"Monocytes and \u03b3\u03b4 T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial","volume":"28","author":"Welton","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2021.116298_bb0125","article-title":"Study of adverse effect profile of parenteral zoledronic acid in female patients with osteoporosis","volume":"10","author":"Kotian","year":"2016","journal-title":"J. Clin. Diagn. Res."},{"issue":"11","key":"10.1016\/j.bone.2021.116298_bb0135","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/107999003322558782","article-title":"Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6","volume":"23","author":"Dicuonzo","year":"2003","journal-title":"J. Interf. Cytokine Res."},{"issue":"3","key":"10.1016\/j.bone.2021.116298_bb0140","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1359\/jbmr.090819","article-title":"Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion","volume":"25","author":"Bertoldo","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"4\u20135","key":"10.1016\/j.bone.2021.116298_bb0145","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/0961203314559633","article-title":"M massarotti, gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction","volume":"24","author":"De Santis","year":"2015","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.bone.2021.116298_bb0150","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/s12888-016-1130-0","article-title":"Electrolyte disorders and aging: risk factors for delirium in patients undergoing orthopedic surgeries","volume":"16","author":"Wang","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.bone.2021.116298_bb0155","first-page":"1309","article-title":"Hypocalcaemia after total knee arthroplasty and its clinical significance","volume":"36","author":"Gai","year":"2016","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.bone.2021.116298_bb0160","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00198-016-3819-9","article-title":"Surgery alters parameters of vitamin D status and other laboratory results","volume":"28","author":"Binkley","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"8","key":"10.1016\/j.bone.2021.116298_bb0165","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00198-010-1473-1","article-title":"HORIZON recurrent fracture trial, association between timing of zoledronic acid infusion and hip fracture healing","volume":"22","author":"Col\u00f3n-Emeric","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2021.116298_bb0170","article-title":"Intravenous bisphosphonate therapy does not delay fracture healing in inter-trochanteric femur fractures - a randomised controlled study","volume":"20","author":"Jalan","year":"2021","journal-title":"IJ Clin. Orthop. Trauma."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221004646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221004646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:43:25Z","timestamp":1762659805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221004646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":33,"alternative-id":["S8756328221004646"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.116298","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.116298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116298"}}